Verastem's promising therapy for LGSOC could position them as a commercial-stage company by 2025. Click here to find out why ...
Following news that the U.S. Food and Drug Administration approved its New Drug Application for avutometinib in combination ...
Verastem, Inc. is on the verge of FDA approval for their combo therapy avutometinib-defactinib, targeting low-grade serous ...
BTIG Research has recently reiterated Verastem Inc (VSTM) stock to Buy rating, as announced on December 31, 2024, according to Finviz. Earlier, on September 30, 2024, Guggenheim had initiated the ...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...
Verastem seeks FDA approval for avutometinib in recurrent LGSOC based on trial results, with a decision expected by June 2025 ...
When compared to the broader market, Verastem Oncology has shown exceptional performance. The company’s stock has surged 30.57% year-to-date, a stark contrast to the S&P 500’s meager performance of -0 ...
Shares of Verastem Oncology (VSTM) are up over 40% at $5.17 in premarket trading Tuesday, following a regulatory update. The ...
BTIG raised the firm’s price target on Verastem (VSTM) to $20 from $13 and keeps a Buy rating on the shares after the company announced the FDA ...
Highlights,FDA grants Priority Review for new treatment combination in recurrent KRAS mutant LGSOC.,Phase 2 trial results ...
On Tuesday, Verastem Inc . (NASDAQ:VSTM), currently trading at $3.67, saw its price target boosted by BTIG from $13.00 to $20.00, while the firm maintained a Buy rating on the stock. According to ...